TNF inhibitors for psoriasis.

Q1 Medicine
Margot Chima, Mark Lebwohl
{"title":"TNF inhibitors for psoriasis.","authors":"Margot Chima,&nbsp;Mark Lebwohl","doi":"10.12788/j.sder.2018.039","DOIUrl":null,"url":null,"abstract":"<p><p>Tumor necrosis factor (TNF)-α has been identified as a key cytokine mediating cutaneous inflammation in the pathogenesis of psoriasis. The TNF inhibitors (TNFi's) infliximab, adalimumab, and etanercept are efficacious, Food and Drug Administration-approved medications for the treatment of moderate-to-severe plaque psoriasis. Each drug has a unique pharmacological profile that can have therapeutic implications when choosing a particular TNFi for a patient. An understanding of these idiosyncrasies can help guide therapeutic decisions for patients with psoriasis that also have inflammatory bowel disease, hepatitis C, hepatitis B, latent tuberculosis, obesity, cardiovascular disease, and heart failure. It can also help when selecting the right treatment for pregnant patients, children and adolescents, or those with insurance constraints or compliance issues.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"134-142"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"28","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in cutaneous medicine and surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/j.sder.2018.039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 28

Abstract

Tumor necrosis factor (TNF)-α has been identified as a key cytokine mediating cutaneous inflammation in the pathogenesis of psoriasis. The TNF inhibitors (TNFi's) infliximab, adalimumab, and etanercept are efficacious, Food and Drug Administration-approved medications for the treatment of moderate-to-severe plaque psoriasis. Each drug has a unique pharmacological profile that can have therapeutic implications when choosing a particular TNFi for a patient. An understanding of these idiosyncrasies can help guide therapeutic decisions for patients with psoriasis that also have inflammatory bowel disease, hepatitis C, hepatitis B, latent tuberculosis, obesity, cardiovascular disease, and heart failure. It can also help when selecting the right treatment for pregnant patients, children and adolescents, or those with insurance constraints or compliance issues.

银屑病的TNF抑制剂。
肿瘤坏死因子(TNF)-α是银屑病发病过程中介导皮肤炎症的关键细胞因子。TNF抑制剂(TNFi)英夫利昔单抗,阿达木单抗和依那西普是有效的,美国食品和药物管理局批准的治疗中度至重度斑块性银屑病的药物。每种药物都有独特的药理学特征,在为患者选择特定的TNFi时可以具有治疗意义。了解这些特质有助于指导银屑病患者同时患有炎症性肠病、丙型肝炎、乙型肝炎、潜伏性肺结核、肥胖、心血管疾病和心力衰竭的治疗决策。它还可以帮助孕妇、儿童和青少年或有保险限制或合规问题的人选择正确的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.90
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Seminars in Cutaneous Medicine and Surgery (SCMS) presents well-rounded and authoritative discussions of important clinical areas, especially those undergoing rapid change in the specialty. Each issue, under the direction of the Editors and Guest Editors selected because of their expertise in the subject area, includes the most current information on the diagnosis and management of specific disorders of the skin, as well as the application of the latest scientific findings to patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信